These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 17277715)
21. Fluoxetine treatment of depressed patients with comorbid anxiety disorders. Sonawalla SB; Farabaugh A; Johnson MW; Morray M; Delgado ML; Pingol MG; Rosenbaum JF; Fava M J Psychopharmacol; 2002 Sep; 16(3):215-9. PubMed ID: 12236627 [TBL] [Abstract][Full Text] [Related]
22. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Cornelius JR; Bukstein OG; Douaihy AB; Clark DB; Chung TA; Daley DC; Wood DS; Brown SJ Drug Alcohol Depend; 2010 Nov; 112(1-2):39-45. PubMed ID: 20576364 [TBL] [Abstract][Full Text] [Related]
23. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Abolfazli R; Hosseini M; Ghanizadeh A; Ghaleiha A; Tabrizi M; Raznahan M; Golalizadeh M; Akhondzadeh S Depress Anxiety; 2011 Apr; 28(4):297-302. PubMed ID: 21456039 [TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of aggression and/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo. Tauscher-Wisniewski S; Nilsson M; Caldwell C; Plewes J; Allen AJ J Child Adolesc Psychopharmacol; 2007 Oct; 17(5):713-8. PubMed ID: 17979590 [TBL] [Abstract][Full Text] [Related]
25. Factors Related to Placebo Response in Randomized, Double-Blind Clinical Trials of Antidepressants in Children and Adolescents: A Meta-regression Analysis. Okubo R; Matsui K; Narukawa M Clin Drug Investig; 2023 Jun; 43(6):383-391. PubMed ID: 37222973 [TBL] [Abstract][Full Text] [Related]
26. Desvenlafaxine Versus Placebo in the Treatment of Children and Adolescents with Major Depressive Disorder. Atkinson S; Lubaczewski S; Ramaker S; England RD; Wajsbrot DB; Abbas R; Findling RL J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):55-65. PubMed ID: 29185786 [TBL] [Abstract][Full Text] [Related]
27. Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study. Kowatch RA; Carmody TJ; Emslie GJ; Rintelmann JW; Hughes CW; Rush AJ J Affect Disord; 1999 Aug; 54(3):269-76. PubMed ID: 10467970 [TBL] [Abstract][Full Text] [Related]
28. A comparison of various methods of measuring antidepressant medication adherence among children and adolescents with major depressive disorder in a 12-week open trial of fluoxetine. Nakonezny PA; Hughes CW; Mayes TL; Sternweis-Yang KH; Kennard BD; Byerly MJ; Emslie GJ J Child Adolesc Psychopharmacol; 2010 Oct; 20(5):431-9. PubMed ID: 20973714 [TBL] [Abstract][Full Text] [Related]
29. Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial. Emslie GJ; Ventura D; Korotzer A; Tourkodimitris S J Am Acad Child Adolesc Psychiatry; 2009 Jul; 48(7):721-729. PubMed ID: 19465881 [TBL] [Abstract][Full Text] [Related]
30. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Davidson JR; Meoni P; Haudiquet V; Cantillon M; Hackett D Depress Anxiety; 2002; 16(1):4-13. PubMed ID: 12203668 [TBL] [Abstract][Full Text] [Related]
32. Treating a broader range of depressed adolescents with combined therapy. Foster S; Mohler-Kuo M J Affect Disord; 2018 Dec; 241():417-424. PubMed ID: 30145512 [TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. Amsterdam JD; Garcia-España F; Fawcett J; Quitkin FM; Reimherr FW; Rosenbaum JF; Schweizer E; Beasley C J Clin Psychopharmacol; 1998 Dec; 18(6):435-40. PubMed ID: 9864074 [TBL] [Abstract][Full Text] [Related]
34. A review of pharmacotherapy of major depression in children and adolescents. Ambrosini PJ Psychiatr Serv; 2000 May; 51(5):627-33. PubMed ID: 10783181 [TBL] [Abstract][Full Text] [Related]
35. Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine. Tollefson GD; Sayler ME Depress Anxiety; 1996-1997; 4(6):294-311. PubMed ID: 9166658 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Strik JJ; Honig A; Lousberg R; Lousberg AH; Cheriex EC; Tuynman-Qua HG; Kuijpers PM; Wellens HJ; Van Praag HM Psychosom Med; 2000; 62(6):783-9. PubMed ID: 11138997 [TBL] [Abstract][Full Text] [Related]
37. Placebo response rates and potential modifiers in double-blind randomized controlled trials of second and newer generation antidepressants for major depressive disorder in children and adolescents: a systematic review and meta-regression analysis. Meister R; Abbas M; Antel J; Peters T; Pan Y; Bingel U; Nestoriuc Y; Hebebrand J Eur Child Adolesc Psychiatry; 2020 Mar; 29(3):253-273. PubMed ID: 30535589 [TBL] [Abstract][Full Text] [Related]
38. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. Bridge JA; Iyengar S; Salary CB; Barbe RP; Birmaher B; Pincus HA; Ren L; Brent DA JAMA; 2007 Apr; 297(15):1683-96. PubMed ID: 17440145 [TBL] [Abstract][Full Text] [Related]
39. Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS). Nakonezny PA; Mayes TL; Byerly MJ; Emslie GJ J Psychiatr Res; 2015 Sep; 68():346-53. PubMed ID: 26028546 [TBL] [Abstract][Full Text] [Related]
40. Acute and longer-term safety results from a pooled analysis of duloxetine studies for the treatment of children and adolescents with major depressive disorder. Emslie GJ; Wells TG; Prakash A; Zhang Q; Pangallo BA; Bangs ME; March JS J Child Adolesc Psychopharmacol; 2015 May; 25(4):293-305. PubMed ID: 25978741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]